GlassScriptPhysician profile
Cody A Schwartz
NPI 1821529777
$2,547.05
in general payments reported to CMS, 2019-2025
22 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.30 · 2020: $29.20 · 2021: $461 · 2022: $727 · 2023: $556 · 2024: $441 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $403.25 | 2022-2025 | Impella |
| Amgen INC. | $299.43 | 2022-2024 | Repatha |
| Kestra Medical Technology Services, INC. | $236.50 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $193.78 | 2020-2025 | Eliquis |
| Shockwave Medical, INC | $192.74 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.21 | 2021-2025 | Lifevest |
| Cardiovascular Systems INC. | $139.50 | 2021 | |
| Endologix LLC | $137.39 | 2021 | |
| Impulse Dynamics (USA) INC. | $112.33 | 2022 | |
| Abbott Laboratories | $97.28 | 2019-2022 | |
| Pfizer INC. | $80.18 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $79.08 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $78.78 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $60.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.41 | 2022-2025 | Winrevair |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.71 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $48.61 | 2024 | Arcalyst |
| La Jolla Pharmaceutical Company | $23.31 | 2024 | Giapreza |
| Heartflow, INC. | $22.09 | 2024 | |
| Atricure, INC. | $21.10 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.04 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $17.94 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.